About 30% of breast cancers are positive for the Her2 oncogene. Although this gene is implicated in breast cancer, the exact mechanism has been unknown. In this study, the researchers showed that the Her2 oncogene activates two short microRNAs, called miR-27b and miR-23b, which in turn regulate breast cancer progression and lung metastasis. The study also shows, for the first time, that these microRNAs inactivate the function of a tumor suppressor gene called Nischarin, that Dr. Alahari's lab discovered.
Analysis to determine which of a number of cancer-related genes could be potential targets for miR-23b/27b found that only one other gene and Nischarin were directly targeted, and these microRNAs repressed its function. Nischarin is a novel protein that regulates breast cancer cell migration and movement. In a previous study, Dr. Alahari found that breast tumor growth and metastasis were reduced in the samples where they manipulated the overproduction of Nischarin.
"Our data for the first time show that these two microRNAs are highly expressed in breast cancer patients, and we were able suppress the expression of microRNAs using a novel antisense compound that led to inhibition of breast tumor growth in a mouse model," notes Dr. Alahari. "This study will be helpful in developing novel breast cancer therapeutic drugs that target mciroRNAs in breast cancer patients."
Excluding skin cancer, breast cancer is the most common type of cancer among women in the United States. The American Cancer Society estimates 232,340 new cases of invasive breast cancer among American women this year, and 2,240 among men in the US, with 39,620 deaths in women and 410 deaths in men.
Risk factors include aging, weight gain, combined hormone therapy, physical inactivity, and alcohol consumption. A family history increases risk, as does never having had children or having a first child after age 30. Mammography can often detect breast cancer at an early stage when treatment options are greatest and a cure is possible.
Researchers from the Cleveland Clinic, Regulus Therapeutics, and the University of Texas MD Anderson Cancer Center also contributed.
The research was supported by grants from the National Institutes of Health, the Susan Komen Foundation, the Louisiana Board of Regents, and the Louisiana Cancer Research Consortium among others.
Louisiana State University Health Sciences Center
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Louisiana State University Health Sciences Center. "New Drug Target For Her-2 Related Breast Cancer." Medical News Today. MediLexicon, Intl., 24 Jan. 2013. Web.
24 May. 2017. <http://www.medicalnewstoday.com/releases/255250.php>
Louisiana State University Health Sciences Center. (2013, January 24). "New Drug Target For Her-2 Related Breast Cancer." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.